Is CJC-1295 / Ipamorelin Safe? Side Effects, Labs and Who Should Avoid It

The main human evidence is the 2006 Journal of Clinical Endocrinology and Metabolism work by Teichman and colleagues: two randomized, placebo-controlled, double-blind, ascending-dose studies in healthy adults aged 21 to 61, lasting 28 and 49 days. A single subcutaneous injection raised mean growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days. No serious adverse reactions were reported, and the authors described the drug as safe and relatively well tolerated, particularly at the lower two of the four doses.

A second 2006 paper in the same journal, by Ionescu and Frohman, sampled blood every 20 minutes overnight in healthy men before and one week after a single injection. Pulse frequency and size did not change, but trough levels between pulses rose about 7.5-fold, mean growth hormone rose 46 percent and IGF-1 rose 45 percent. That is the basis for the claim that CJC-1295 preserves pulsatility, and also the reason a careful reader notes that "preserved pulsatility" sat alongside a marked rise in the baseline between pulses.

The 1999 Pharmaceutical Research study established dose-proportional kinetics and the short half-life in healthy men. The 2014 study in the International Journal of Colorectal Disease was a phase 2, multicenter, double-blind, placebo-controlled trial in 117 adults recovering from bowel resection, dosed twice daily in hospital for up to seven days. It was designed around gut motility and did not separate from placebo on efficacy; its value here is the safety arm, where treatment-emergent adverse events occurred in 87.5 percent on ipamorelin and 94.8 percent on placebo, and the authors concluded the drug was well tolerated. Neither study resembles wellness use: neither used subcutaneous dosing over months, combined ipamorelin with a GHRH analog, or measured IGF-1 over time.

In rats, ipamorelin was reported to induce longitudinal bone growth (Growth Hormone & IGF Research, 1999), to increase bone mineral content in adult females (Journal of Endocrinology, 2000) and to counteract glucocorticoid-induced loss of bone formation (Growth Hormone & IGF Research, 2001). A 2004 paper in Neuro Endocrinology Letters described ipamorelin evoking insulin release from the isolated rat pancreas, and a 2001 paper in Biochemical and Biophysical Research Communications reported secretagogues stimulating adiposity in mice independently of growth hormone, consistent with the appetite effect people report. For CJC-1295, a 2006 paper in the American Journal of Physiology, Endocrinology and Metabolism reported once-daily dosing normalizing growth in GHRH-knockout mice.

Because ipamorelin has so little long-term human data, physicians reason from the closest well-studied compound in its class. Ibutamoren (MK-677) is an oral ghrelin mimetic, not a peptide, but it acts on the same receptor. A 2008 randomized, placebo-controlled trial in the Annals of Internal Medicine gave it daily to 65 healthy adults aged 60 to 81 for one to two years: growth hormone and IGF-1 rose to young-adult levels, fasting glucose rose by an average of 5 mg/dL, insulin sensitivity fell, cortisol rose modestly, and the most frequent side effects were an appetite increase that subsided within a few months and transient, mild lower-leg swelling and muscle pain.

For what too much growth hormone itself looks like, the reference point is the 2002 JAMA trial by Blackman and colleagues, which gave recombinant growth hormone to healthy adults aged 65 to 88 for 26 weeks. Edema occurred in 39 percent of women on growth hormone versus none on placebo; carpal tunnel symptoms in 32 percent of men on growth hormone plus testosterone; arthralgias in 41 percent of men on growth hormone; and diabetes or glucose intolerance in 18 growth hormone-treated men versus seven who were not. That trial used injected hormone, not a secretagogue, and its rates should not be transferred to CJC-1295 / ipamorelin. It is cited because it defines the pattern: fluid, joints, nerves and glucose are what excess growth hormone looks like.

There are no randomized human trials of CJC-1295 and ipamorelin given together, none of either compound for wellness, body composition, sleep or recovery, and no published long-term safety cohort for either. The 2018 Sexual Medicine Reviews paper reached the same conclusion for the class: few long-term controlled studies exist, the compounds are generally well tolerated in those that do, there is some concern about blood glucose, and the safety of long-term use, including cancer incidence, has not been evaluated.

None of these is a reason to stop on its own. The flushing and head-rush feeling is a GHRH-receptor effect, usually most noticeable in the first weeks. Vivid dreams track evening dosing and the change in slow-wave sleep a growth hormone pulse produces; the 2000 JAMA paper on age-related change in slow-wave sleep and growth hormone is the background for why growth-axis peptides are usually dosed at night. Appetite surprises people most, because ghrelin is the hunger hormone and ipamorelin is a ghrelin mimetic.

The uncommon block is not a list of rare dangers. It is the recognized pattern of growth hormone above requirement, and the fix is almost always a smaller dose. Growth hormone promotes sodium and water retention, which shows as puffy hands and ankles; soft-tissue swelling at the wrist is the mechanism behind carpal-tunnel-type tingling, and joint ache follows the same fluid shift. All three respond to dose reduction. With CJC-1295 in the picture the response is slower than with ipamorelin alone, because its effect tapers over days rather than hours, so a prescriber acts on the first report rather than waiting for a pattern.

Allergic reactions to peptides are uncommon but real: facial or throat swelling, hives spreading beyond the injection site, or breathing difficulty are emergency-care events first. Persistent severe headache or a change in vision on a growth-axis peptide is a same-day call, far more likely unrelated, but pituitary symptoms are not something to watch at home. Numbness that does not resolve after a dose reduction means the reduction was not the answer and the drug should stop while a physician looks. Sterility of the preparation is the pharmacy's responsibility; what Pepti checks and publishes is on the quality page and in lab results.

IGF-1 is the marker because it integrates the growth hormone signal over days rather than minutes. The reference range is age-adjusted, and the target is a result inside the range for your age, typically the middle or upper-middle of it, not the top and not above. An IGF-1 above the age-adjusted range on a growth-axis peptide is not a success; it is the biochemical version of the uncommon block, and it means the dose comes down.

The 1998 pharmacology work addressed this directly: no ACTH or cortisol release above what GHRH itself produces, and no effect on prolactin, at doses far above the growth hormone-releasing dose. CJC-1295 acts on the GHRH receptor and is not associated with cortisol release. The class caveat is the 2008 ibutamoren trial, which reported a modest cortisol rise over a year on a different ghrelin mimetic; there is no comparable long-duration data for ipamorelin, so a prescriber with reason to care can add cortisol to the panel.

Increased appetite is an on-target effect rather than a side effect in the usual sense, and in the ibutamoren trial it subsided within a few months. For someone whose goal is weight management this is worth naming at the outset; a physician may prefer tesamorelin, a GHRH analog with human trial data in visceral fat, or a different product altogether. Anyone with a history of an eating disorder should raise it specifically.

"CJC-1295" is used in circulation for two different molecules. The version in the 2006 human trials carries the drug affinity complex and binds albumin, giving it a half-life of about a week. A version without that modification, sometimes written CJC-1295 no-DAC or modified GRF(1-29), is a much shorter-acting GHRH analog, and online dosing lore often does not say which it means. What applies to you is your prescription and the pharmacy's label. The long-acting form corrects slowly after a dose reduction, so it is dosed conservatively from the start.

Growth hormone excess enlarges soft tissue and promotes fluid retention, both of which can worsen obstructive sleep apnea; untreated severe apnea is on the exclusion table for that reason, while treated apnea with a physician's knowledge is usually workable. Untreated hypothyroidism blunts the growth hormone response and changes how IGF-1 should be read, so it is treated first. And because these peptides act on the pituitary, any known pituitary condition, a prior adenoma, surgery or radiation, generally means the physician looks elsewhere.

If you are taking testosterone alongside this, that belongs in the same conversation rather than a separate one. Testosterone and growth hormone have additive effects on lean mass and on the side-effect profile: in the Blackman trial the carpal-tunnel signal was highest in men receiving both. See can you take peptides with testosterone.

Pepti supplies the pairing alone, with sermorelin added as CJC-1295 / Ipamorelin / Sermorelin, and within blends such as REVIVE, SERENITY, SHRED and TITAN. Sermorelin is a shorter-acting GHRH analog with a longer human record, including 1990s trials in older adults in the Journal of Clinical Endocrinology and Metabolism; adding it to CJC-1295 stacks two GHRH-receptor signals of different duration, and adding tesamorelin, as in TITAN, does the same. None of these combinations has comparative safety data, and the IGF-1 target is the same whichever is used. Two growth-axis products from separate prescriptions should not be combined without the prescriber knowing about both. See CJC-1295 vs sermorelin.

Neither CJC-1295 nor ipamorelin is an FDA-approved drug; no manufacturer has taken either through the approval process, so there is no approved product and no FDA-reviewed label. Compounded medications are never FDA approved as finished products: a state-licensed pharmacy prepares them to a physician's prescription for an individual patient, and the pharmacy is accountable for the identity, purity and sterility of what it dispenses. See are peptides FDA approved.

Both substances were nominated for the FDA's list of bulk drug substances that may be used in 503A compounding, and both went before the Pharmacy Compounding Advisory Committee (PCAC) in late 2024.

Ipamorelin was heard on October 29, 2024. The FDA proposed that ipamorelin (free base) and ipamorelin acetate not be included on the 503A Bulks List, and the committee agreed: on whether ipamorelin should be placed on the list, the vote was 0 yes, 12 no, 1 abstaining, for both forms. The minutes record that members voting no cited a lack of information supporting safety and efficacy in the available data for the two uses the nomination relied on, growth hormone deficiency and postoperative ileus.

CJC-1295 was heard on December 4, 2024. The FDA proposed that five CJC-1295-related substances (the free base, the acetate, and the DAC free base, acetate and trifluoroacetate) not be included. On whether CJC-1295 (free base) should be placed on the list, the vote was 0 yes, 13 no; the acetate drew one yes and 12 no; the three DAC forms were each 0 to 13. The minutes record one member's comment on the lack of evidence for effectiveness.

These are advisory votes on whether the substances should be added to the 503A Bulks List. They are not a finding of a documented harm signal; the recorded reasoning is about the absence of evidence. They are also not a ban. The FDA issues its own determination through rulemaking after weighing the committee's advice.

The FDA maintains a document sorting nominated substances into three categories: Category 1 (under evaluation, with an interim enforcement policy), Category 2 (significant safety concerns) and Category 3 (nominated without adequate support). In the version updated May 14, 2026, neither CJC-1295 nor ipamorelin appears in any of the three. The FDA's 503A bulk drug substances page carries the same May 14, 2026 date and does not mention either compound. Neither was on the agenda when the committee met again on July 23 and 24, 2026, which dealt with BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and epitalon.

So the accurate description in September 2026 is: not FDA approved; recommended against inclusion on the 503A Bulks List by the advisory committee in late 2024 on grounds of insufficient evidence; not currently listed in any 503A category; and awaiting the FDA's final action on the list. That is the status Pepti's physicians prescribe against and the pharmacy compounds against. It does not change the clinical safety picture, because the committee looked at the same thin human evidence this page describes. It does mean that any provider calling these compounds "FDA approved" or "on the FDA list" is wrong.

The baseline IGF-1 is the single most useful number, because it establishes where your axis sits before anything is added. Fasting glucose and, where history warrants, HbA1c establish glucose handling; thyroid function is checked because hypothyroidism changes the whole picture. The history questions, cancer, sleep apnea, pituitary disease, eating disorder, are asked because the answers change the decision.

CJC-1295's long half-life means IGF-1 rises over weeks rather than days and settles in the four-to-twelve-week window. A repeat IGF-1 there shows whether the dose lands inside the range for your age and sex; a result that is high-normal in a 30-year-old may be above range in a 60-year-old. If it is above, the dose comes down. If glucose was borderline at baseline, it is repeated here.

Treatment is long-term, on 28-day refills, and the monitoring schedule is set by your physician against your results. For a normal baseline and an in-range follow-up, that is typically IGF-1 and glucose at intervals rather than monthly. For prediabetes, a cancer history or a borderline result, it is closer.